Recent Posts
- HealthInvest June 2026: A Look Inside Australia's Healthcare Innovations16 Jun 2026
- HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences19 May 2026
- Lifesaving Capital: How impact investing is shaping the future of biotech30 Apr 2026
- Investor Relations: the quiet advantage powering ASX microcaps28 Nov 2025
- HealthInvest Sydney: Life Sciences in the Investor Spotlight06 Oct 2025
Archives

NEWSLETTER MARCH 2022
08 Mar 2022 · Cherie Hartley
IR Department celebrates International Women's Day 2022
YouTube video player
Read article
NEWSLETTER MARCH 2022
16 Feb 2022 · Paul Langley
Learn more about HaemaLogix’s ground-breaking KappaMab technology
KappaMab is a monoclonal antibody developed by HaemaLogiX to treat blood cancers, with an initial focus on multiple myeloma.
Read article